Vireo Growth (VREOF) Change in Accured Expenses (2020 - 2025)
Vireo Growth (VREOF) posted Change in Accured Expenses of $10.1 million for Q4 2025, up 154.18% sequentially from -$18.6 million in Q3 2025, and up 747.1% YoY from $1.2 million in Q4 2024.
Vireo Growth (VREOF) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Vireo Growth has reported Change in Accured Expenses for 6 years, with the latest figure at $10.1 million in Q4 2025.
- Quarterly Change in Accured Expenses rose 747.1% year-over-year to $10.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.7 million (down 462.65% YoY) and the FY2025 annual result came in at -$8.7 million, down 462.65% from the prior year.
- Change in Accured Expenses climbed to $10.1 million in Q4 2025 per VREOF's latest filing, from -$18.6 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $10.1 million in Q4 2025 and troughed at -$18.6 million in Q3 2025.
- A 5-year average of -$284488.8 and a median of $607847.0 in 2024 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 932.47% in 2025, down 797218.55% in 2025.
- Over 5 years, Change in Accured Expenses stood at $5.2 million in 2021, then sank by 160.13% to -$3.1 million in 2022, then advanced by 25.38% to -$2.3 million in 2023, then soared by 150.95% to $1.2 million in 2024, then surged by 747.1% to $10.1 million in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $10.1 million, -$18.6 million, and -$2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Vireo Growth | 492.35 Mn | 350.05 Mn | 95.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.08 Mn |
| Dec 31, 2025 | 10.08 Mn |
| Sep 30, 2025 | -18.61 Mn |
| Sep 30, 2025 | -18.61 Mn |
| Jun 30, 2025 | -1.99 Mn |
| Jun 30, 2025 | -1.99 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | -2,334.00 |
| Sep 30, 2024 | -2,334.00 |
| Jun 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 174,340.00 |
| Mar 31, 2024 | 174,340.00 |
| Dec 31, 2023 | -2.34 Mn |
| Dec 31, 2023 | -2.34 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Sep 30, 2023 | -1.48 Mn |